摘要
重症社区获得性肺炎(CAP)一直是临床最常见的、死亡率及发病率高居感染性疾病榜首的疾病,尽管近年来在病原学诊断、抗生素治疗以及生命支持等方面有显著的进展,但是肺炎死亡率并没有下降。为改善预后,重症肺炎的辅助抗炎治疗引发关注。在过去的几十年中,除肺孢子菌肺炎外,激素作为辅助治疗并未获得理想的结果。但是重症疾病相关的激素缺乏患者病理生理及一些激素治疗的临床试验结果提示,其在呼吸生理、免疫及血流动力学等均有获益。本文参阅近年来关于在重症CAP激素使用的研究文献,对其临床结果进行分析,并就进一步研究提出建议。
Severe community-acquired pneumonia （CAP） is associated with significant morbidity and mortality and is the most common cause of death from infectious diseases despite significant advances in etiological investigation, antimicrobial therapy, and improvements in supportive care. To improve patient＇s prognosis, the adjunctive anti-inflammatory therapies for severe infections have been concerned. Except pneumocystis jirovecii pneumonia, corticosteroid treatment was unsatisfactory in the past several decades. Nevertheless, with the concept of critical illness-related corticosteroid insufficiency （CIRCI） and the results of a few corticosteroid clinical trials showed resPiratory, immune, and hemodynamic benefits, in this article, we reviewed recent peerreviewed reports to determine whether systemic corticosteroids have an impact on the outcomes of patients with severe CAP. In addition, we suggest some opinions in further research.
出处
《临床药物治疗杂志》
2012年第3期1-5,共5页
Clinical Medication Journal
